New hope for brain lining cancer: immunotherapy injected directly into spinal fluid

NCT ID NCT03025256

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This early-phase trial is testing whether the immunotherapy drug nivolumab can help people with melanoma or lung cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). The drug is given both through a vein and directly into the spinal fluid via a lumbar puncture. The study aims to find the safest dose and see if it can help patients live longer. About 75 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab (a cancer immunotherapy drug)
What this could lead to
If it works, this could offer a new treatment option for people with cancer that has spread to the lining of the brain and spinal cord, a condition with very few options.
What could go wrong
This is an early Phase I trial with only 75 participants, so it is primarily testing safety and dosing. It may not improve survival, and side effects from the immunotherapy or the spinal injections could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACRAL LENTIGINOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.